SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

The upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with a Nov. 22 target date, is driving discussion. Bulls see the amended filings upper-limb data, rare-disease policy discussions and launch-related hiring as encouraging, while skeptics cite the prior negative advisory-committee review and ongoing uncertainty about efficacy and the potential label.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a treatment for recurrent respiratory papillomatosis has renewed focus on competition for Precigens PAPZIMEOS. Traders debate whether the new entrant threatens Precigens first-mover commercial lead or whether the selloff overstates the risk, citing differences in approval status, clinical data and commercialization challenges.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA add-on reimbursement for DefenCath could decline after early 2027 has driven concern about pricing and sales. Traders are divided: some see the comments as a threat to DefenCaths economics, while others argue DaVitas outlook is preliminary and point to CMSs published estimate as a counterpoint.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to fresh 52-week highs ahead of anticipated Q3 earnings has traders focused on whether BRIUMVI growth can support the move, while unconfirmed buyout speculation and short-squeeze talk add to the excitement. Some traders attribute the gains to earnings expectations rather than a potential acquisition.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 leukemia trial reaching its prespecified 80th death event has put final analysis and the topline readout in focus. Traders are sharply divided: bulls expect GPS to show a survival benefit, while skeptics question the trial assumptions and whether it can outperform the physicians-choice arm; shares have sold off despite the milestone.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq/tech selloff, amplified by Intels weak outlook, has focused discussion on whether heavy AI infrastructure spending will deliver adequate returns and whether the AI trade is overvalued. Traders are split between treating the decline as an oversold buying opportunity and warning that further losses may follow; concerns about persistent inflation and higher rates add pressure.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadogs sharp selloff followed quarterly results that beat expectations and raised its annual outlook, but traders focused on guidance suggesting slower near-term growth. Debate centers on whether a major AI customers reported usage reduction signals broader consumption softness, with valuation concerns adding pressure while some investors view the decline as an overreaction.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons quarterly results beat expectations, with Eylea HD and Sanofi collaboration revenue tied to Dupixent highlighted as key growth drivers. Traders welcomed the sharp rally and breakout, while some focused on whether newer drugs and pipeline programs can sustain growth.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, E-Vapor Products and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The E-Vapor Products segment contracts with third-party importers to supply all of its products and sells its e-vapor products to customers in the United States. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altrias quarterly report, higher full-year outlook and expanded share-repurchase plan are driving attention as shares approach recent highs. Traders are largely upbeat, while some are disappointed the dividend was unchanged and others attribute the strength to a broader rotation into defensive, high-yield stocks.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA is drawing attention amid a broad market selloff, as weak Amazon and Intel results and worries over AI spending weigh on stocks; rising oil prices and persistent inflation are adding concern about further Fed tightening. Traders are mostly bearish, though some see the weakness as a rotation out of tech rather than a broader market breakdown.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
